Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 14Gastrointestinal 10Gynecologic 6Tumor-Agnostic 3Genitourinary 3Other solid neoplasm 2Sarcoma 1Other hematologic neoplasm 1NET 1Endocrine 1CNS 1Breast 1

Conditions

Mesothelioma, Malignant 1Mesothelioma 1

Interventions

pembrolizumab 26Pemetrexed 26Cisplatin 25Nivolumab 22Carboplatin 16Paclitaxel 14Gemcitabine 12Ipilimumab 11tislelizumab 8durvalumab 8Ramucirumab 8Docetaxel 8talazoparib 7Fluorouracil 7Radiotherapy 6Capecitabine 6tremelimumab 5cobimetinib 5atezolizumab 5adavosertib 5Radiosurgery 5Cyclophosphamide 5Bevacizumab 5olaparib 4avelumab 4Temozolomide 4Sunitinib 4Specimen Handling 4Platinum 4PM 01183 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × nintedanib × Other solid neoplasm × Clear all
NCT02568449 2021-12-09

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
20 enrolled 11 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01907100 2019-03-18

Nintedanib (BIBF 1120) in Mesothelioma

Boehringer Ingelheim

Phase 2/3 Terminated
545 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡